- Johnson & Johnson (JNJ) Q3 results:
- Revenues: $21,082M (+1.7%); Consumer Health: $3,514M (+1.3%) vs. consensus of $3.42B.
- Pharmaceutical: $11,418M (+5.0%); Medical Devices: $6,150M (-3.7%) compared to consensus of $5.45B.
- Key Product Sales: Remicade: $921M (-18.9%); Simponi/Simponi Aria: $592M (+0.9%); Stelara: $1,947M (+14.7%); Tremfya: $327M (+13.1%); Edurant/rilpivirine: $236M (+8.1%); Prezista/Prezcobix/Rezolsta/Symtuza: $526M (+3.5%); Darzalex: $1,099M (+43.8%); Imbruvica: $1,031M (+11.9%); Invega Sustennn/Xeplion/Trinza/Trevicta: $926M (+8.8%); Zytiga: $590M (-20.4%); Xarelto: $630M (+2.9%); Opsumit: $392M (+13.0%); Uptravi: $260M (+23.6%); Invokana/Invokamet: $224M (+24.7%); Erleada: $206M.
- Net Income: $3,554M (+102.7%); EPS: $1.33 (+101.5%); non-GAAP Net Income: $5,868M (+3.5%); non-GAAP EPS: $2.20 (+3.8%).
-
2020 Guidance: Revenues: $81.2B-82.0B from $79.9B-81.4B ($80.66B consensus). Non-GAAP EPS: $7.95-8.05 from $7.75-7.95 prior ($7.89 consensus).
- Also, yesterday the news made round that the study of company's COVID-19 vaccine has been temporarily halted due to an unexplained illness in a trial participant.
- Shares are down 1% premarket.
- Previously: Johnson & Johnson beats on earning, raises FY20 guidance (Oct. 13)